Clinical Trial Update: Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety of two applications of PEP005 topical gel for superficial basal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• PEP005 Topical Gel (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Basal Cell Carcinoma | Phase 2 | Status: COMPLETED